February 1, 2015
Bone Therapeutics recently announced it will undertake efforts to expand its offerings to include osteoblastic cell-matrix products.
These offerings, which will be used to treat large bone defects, will be a variant of the company’s osteoblastic cells within a 3-D bioprinted scaffold. The company believes this will become a favorable alternative to the current standard of care, bone autograft, according to a press release.
The company’s venture has been met with support from the government of the Walloon region, which has given Bone Therapeutics €1 million in non-dilutive, recoverable cash advances to finance the company’s efforts.